We aimed to assess the clinical utility of tau PET imaging as a standalone predictor of AD-relevant cognitive decline by testing its ability to detect the subgroup of Aβ(+) individuals who experience prospective disease progression in Alzheimer’s Disease Neuroimaging Initiative (ADNI) participants. The gene discussed is MAPT; the disease is Alzheimer disease.